Zoetis Inc
ZTS · Healthcare · Pharmaceuticals
Updated 25 min ago · data delayed ≥15 min
IconicScore
ProprietaryRanked #302 of 500 by Iconic Score · #38 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.
Get the free morning email
The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →
Price performance
Export history · AnalystThis insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.
Upgrade to AnalystThis is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.
Upgrade to EnterpriseIconic Profile
Zoetis Inc (ZTS) is a leading global animal health company specializing in the discovery, development, and commercialization of veterinary pharmaceuticals and vaccines. With a market capitalization of $33.3 billion, Zoetis holds a strong position in the healthcare sector, focusing on improving the health and productivity of livestock and companion animals. The company's extensive portfolio includes products for pain management, anti-infectives, and reproductive health, catering to a diverse range of animal species. Zoetis is recognized for its commitment to innovation, investing significantly in research and development to address evolving animal health challenges. As the demand for sustainable animal protein and pet care continues to rise, Zoetis plays a crucial role in ensuring animal well-being and food safety, making it a significant player in the global healthcare landscape.
IconicOracleAI™ Brief
Zoetis Inc. currently holds an Iconic Score of 43, reflecting challenges in brand perception amid recent headlines highlighting weakening fundamentals and competitive pressures in the animal health sector. Despite receiving FDA approval for a new product aimed at improving treatment accessibility for dogs, concerns about pricing risks and market competition have overshadowed positive developments. The company's brand visibility remains strong at 85/100, indicating a solid presence, yet the overall sentiment reflects caution among investors.
AI-generated explanation of current score drivers. Not investment advice.
Enterprise tier: claim your logo to manage how your brand is represented.